Peter Lamprecht

List of Publications by Year
in descending order

95 papers	3,752 citations	147801 31 h-index	138484 58 g-index
107 all docs	107 docs citations	107 times ranked	4169 citing authors

#	Article	IF	Citations
1	Mechanisms of Autoantibody-Induced Pathology. Frontiers in Immunology, 2017, 8, 603.	4.8	377
2	Peripheral Blood and Granuloma CD4+CD28â^' T Cells Are a Major Source of Interferon-Î³ and Tumor Necrosis Factor-Î± in Wegenerâ€™s Granulomatosis. American Journal of Pathology, 2002, 160, 1717-1724.	3.8	215
3	Nomenclature of Cutaneous Vasculitis. Arthritis and Rheumatology, 2018, 70, 171-184.	5.6	200
4	The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 344-353.	6.4	182
5	Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Stillâ€™s disease. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212608.	0.9	181
6	Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis and Rheumatism, 2000, 43, 226-231.	6.7	165
7	Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nature Communications, 2019, 10, 5120.	12.8	160
8	GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis. Nature Communications, 2018, 9, 5224.	12.8	116
9	Proteinase 3 on apoptotic cells disrupts immune silencing in autoimmune vasculitis. Journal of Clinical Investigation, 2015, 125, 4107-4121.	8.2	101
10	Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway. Blood, 2006, 107, 4440-4448.	1.4	100
11	The Diagnosis and Treatment of Giant Cell Arteritis. Deutsches Ärzteblatt International, 2013, 110, 376-85; quiz 386.	0.9	100
12	International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmunity Reviews, 2016, 15, 1145-1160.	5.8	87
13	International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmunity Reviews, 2017, 16, 523-541.	5.8	87
14	Wegener?s Granulomatosis. Herz, 2004, 29, 47-56.	1.1	79
15	Pathogenetic and Clinical Aspects of Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitides. Frontiers in Immunology, 2018, 9, 680.	4.8	76
16	Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases. Frontiers in Immunology, 2021, 12, 648408.	4.8	76
17	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. Journal of Hepatology, 2017, 66, 1282-1299.	3.7	73
18	Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis. Current Opinion in Rheumatology, 2010, 22, 43-48.	4.3	69

#	Article	IF	Citations
19	Genetic predisposition (NLRP3 V198M mutation) for IL-1â€“mediated inflammation in a patient with Schnitzler syndrome. Journal of Allergy and Clinical Immunology, 2010, 125, 500-502.	2.9	64
20	Differences in CCR5 expression on peripheral blood CD4+CD28â¯ T-cells and in granulomatous lesions between localized and generalized Wegenerâ€™s granulomatosis. Clinical Immunology, 2003, 108, 1-7.	3.2	63
21	Expansion of circulating NKG2D+ effector memory T-cells and expression of NKG2D-ligand MIC in granulomaous lesions in Wegener's granulomatosis. Clinical Immunology, 2008, 127, 144-150.	3.2	63
22	T-helper cells as new players in ANCA-associated vasculitides. Arthritis Research and Therapy, 2011, 13, 236.	3.5	59
23	Nasal carriage of Staphylococcus aureus and endonasal activity in Wegener s granulomatosis as compared to rheumatoid arthritis and chronic Rhinosinusitis with nasal polyps. Clinical and Experimental Rheumatology, 2010, 28, 51-5.	0.8	54
24	Advances in the therapy of Wegener's granulomatosis. Current Opinion in Rheumatology, 2006, 18, 25-32.	4.3	50
25	Diagnostic significance of ANCA in vasculitis. Nature Clinical Practice Rheumatology, 2006, 2, 174-175.	3.2	48
26	Changes in the composition of the upper respiratory tract microbial community in granulomatosis with polyangiitis. Journal of Autoimmunity, 2019, 97, 29-39.	6.5	41
27	Heterogeneity of CD4 and CD8+ memory T cells in localized and generalized Wegener's granulomatosis. Arthritis Research, 2003, 5, R25.	2.0	36
28	Frequency of proteinase 3 (PR3)-specific autoreactive T cells determined by cytokine flow cytometry in Wegener's granulomatosis. Journal of Autoimmunity, 2004, 22, 79-85.	6.5	36
29	Wegenerâ€™s Granulomatosis: The Current View. Clinical Reviews in Allergy and Immunology, 2008, 35, 19-21.	6.5	36
30	Environmental factor and inflammation-driven alteration of the total peripheral T-cell compartment in granulomatosis with polyangiitis. Journal of Autoimmunity, 2017, 78, 79-91.	6.5	34
31	Coâ€occurrence of autoantibodies in healthy blood donors. Experimental Dermatology, 2014, 23, 519-521.	2.9	32
32	Granuloma formation in ANCAâ€associated vasculitides. Apmis, 2009, 117, 32-36.	2.0	31
33	Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial. Trials, 2021, 22, 543.	1.6	31
34	Cartilage Destruction in Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Is Mediated by Human Fibroblasts after Transplantation into Immunodeficient Mice. American Journal of Pathology, 2012, 180, 2144-2155.	3.8	30
35	TNF-Î± inhibitors in systemic vasculitides and connective tissue diseases. Autoimmunity Reviews, 2005, 4, 28-34.	5.8	26
36	Longitudinal analysis of frequency and reactivity of epsteinâ€“barr virusâ€specific T lymphocytes and their association with intermittent viral reactivation. Journal of Medical Virology, 2012, 84, 119-131.	5.0	24

#	Article	IF	Citations
37	New insights into the epidemiology of ANCA-associated vasculitides in Germany: results from a claims data study. Rheumatology, 2021, 60, 4868-4873.	1.9	23
38	Granulomatous Inflammation in ANCA-Associated Vasculitis. International Journal of Molecular Sciences, 2021, 22, 6474.	4.1	23
39	Update on Clinical, Pathophysiological and Therapeutic Aspects in ANCAAssociated Vasculitides. Current Drug Discovery Technologies, 2009, 6, 241-251.	1.2	20
40	Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes. Pharmacogenomics, 2016, 17, 367-374.	1.3	19
41	In situ detection of PR3-ANCA+ B cells and alterations in the variable region of immunoglobulin genes support a role of inflamed tissue in the emergence of auto-reactivity in granulomatosis with polyangiitis. Journal of Autoimmunity, 2018, 93, 89-103.	6.5	19
42	Nomenclature of cutaneous vasculitides â€“ German translation of the dermatologic addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1425-1432.	0.8	18
43	Transfer of PBMC From SSc Patients Induces Autoantibodies and Systemic Inflammation in Rag2-/-/IL2rg-/- Mice. Frontiers in Immunology, 2021, 12, 677970.	4.8	17
44	T cell alterations and lymphoid neogenesis favoring autoimmunity in Wegener's granulomatosis. Arthritis and Rheumatism, 2007, 56, 1725-1727.	6.7	16
45	Refractory Central Nervous System Vasculitis and Gastrocnemius Myalgia Syndrome in Crohn's Disease Successfully Treated with Anti-Tumor Necrosis Factor-Î± Antibody. Seminars in Arthritis and Rheumatism, 2009, 38, 337-347.	3.4	16
46	Lower numbers of FoxP3 and CCR4 co-expressing cells in an elevated subpopulation of CD4+CD25high regulatory T cells from Wegener's granulomatosis. Clinical and Experimental Rheumatology, 2010, 28, 72-80.	0.8	16
47	Aberrant cytokine pattern of the nasal mucosa in granulomatosis with polyangiitis. Arthritis Research and Therapy, 2012, 14, R203.	3.5	15
48	Nomenklatur der kutanen Vaskulitiden â€“ deutschsprachige Definitionen des Dermatologischen Anhanges zur Chapel Hill Consensus Conference. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1425-1433.	0.8	15
49	Alterations in the phenotype of CMV-specific and total CD8+ T-cell populations in Wegenerâ€™s granulomatosis. Cellular Immunology, 2003, 224, 1-7.	3.0	14
50	A brief history of Wegener's granulomatosis: On limited, localized, and generalized forms of the disease: comment on the article by the Wegener's granulomatosis Etanercept Trial Research Group. Arthritis and Rheumatism, 2004, 50, 334-335.	6.7	14
51	Current State of Biologicals in the Management of Systemic Vasculitis. Annals of the New York Academy of Sciences, 2007, 1110, 261-270.	3.8	14
52	CD28- T cells display features of effector memory T cells in Wegener's granulomatosis. Kidney International, 2004, 65, 1113.	5.2	13
53	The low-penetrance R92Q mutation of the tumour necrosis factor superfamily 1A gene is neither a major risk factor for Wegener's granulomatosis nor multiple sclerosis. Annals of the Rheumatic Diseases, 2007, 66, 1266-1267.	0.9	12
54	Biological therapies: new treatment options for ANCA-associated vasculitis?. Expert Opinion on Biological Therapy, 2007, 7, 521-533.	3.1	12

#	Article	IF	Citations
55	Intra- and inter-rater reliability of endonasal activity estimation in granulomatosis with polyangiitis (WegenerÂ´s). Clinical and Experimental Rheumatology, 2012, 30, S22-8.	0.8	12
56	Methotrexate plus leflunomide for the treatment of relapsingWegener's granulomatosis. A retrospective uncontrolled study. Clinical and Experimental Rheumatology, 2010, 28, 67-71.	0.8	11
57	Distinct proteinase 3-induced cytokine patterns in WegenerÂ´s granulomatosis, Churg-Strauss syndrome, and healthy controls. Clinical and Experimental Rheumatology, 2011, 29, S57-62.	0.8	11
58	Antineutrophil cytoplasmic antibody-associated vasculitis: autoinflammation, autodestruction and autoimmunity â€“ key to new therapies. Trends in Immunology, 2008, 29, 587-588.	6.8	10
59	Antimicrobial peptides in nasal secretion and mucosa with respect to S. aureus colonisation in WegenerÂ´s granulomatosis. Clinical and Experimental Rheumatology, 2011, 29, S49-56.	0.8	10
60	Rituximab in Refractory Wegener's Granulomatosis: Favorable or Not?. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 815a-816.	5.6	9
61	Increased frequency of CCR4+ and CCR6+ memory T-cells including CCR7+CD45RAmed very early memory cells in granulomatosis with polyangiitis (Wegener`s). Arthritis Research and Therapy, 2012, 14, R73.	3.5	8
62	VÎ´2 T cell deficiency in granulomatosis with polyangiitis (Wegener's granulomatosis). Clinical Immunology, 2013, 149, 65-72.	3.2	8
63	A little help from our friends: what an epidemiologic study teaches us about autoinflammation, granuloma and proteinase-3-specific antineutrophil cytoplasmic autoantibodies. Nephrology Dialysis Transplantation, 2008, 23, 3743-3745.	0.7	6
64	Acute Inflammatory Syndrome with Elevated Procalcitonin Induced by Mycophenolate Sodium: Figure 1.. Journal of Rheumatology, 2012, 39, 658-659.	2.0	6
65	Flow cytometric characterization of â€œearlyâ€•and â€œlate differentiatedâ€•Tâ€•cells including PR3â€•specific cells in granulomatosis with polyangiitis (Wegener's). Cytometry Part B - Clinical Cytometry, 2012, 82B, 173-175.	1.5	6
66	The Joint Vasculitis Registry in German-speaking countries (GeVas) â€“ a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitis. BMC Rheumatology, 2021, 5, 40.	1.6	6
67	Local Expression of C-Reactive Protein Is Associated with Deteriorating Graft Function in Acute and Chronic Failure of Kidney Transplants. Nephron Clinical Practice, 2011, 117, 390-397.	2.3	5
68	Decreased endothelin receptor A autoantibody levels are associated with early ischaemic events in patients with giant-cell arteritis. Annals of the Rheumatic Diseases, 2019, 78, 1443-1444.	0.9	5
69	Clinical images: Saddlenose deformity caused by destructive granulomatous inflammation in Wegener's granulomatosis. Arthritis and Rheumatism, 2008, 58, 834-834.	6.7	4
70	Comment on: Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum. Rheumatology, 2020, 59, 1185-1187.	1.9	4
71	Anti-Citrullinated Protein-Peptide Antibodies in Rheumatoid Arthritis. Deutsches Ärzteblatt International, 2009, 106, 157-8.	0.9	4
72	Diagnosis of deficiency of adenosine deaminase 2 with early onset polyarteritis nodosa in an adult patient with a novel compound heterozygous CECR1 mutation. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 177.	0.8	4

#	Article	IF	Citations
73	TNF-Inhibitors in Wegenerâ€™s Granulomatosis. Kidney and Blood Pressure Research, 2005, 28, 62-62.	2.0	3
74	L20. Memory T-cells in vasculitis. Presse Medicale, 2013, 42, 560-563.	1.9	3
75	Extracorporeal membrane oxygenation in ANCA-associated vasculitis. Autoimmunity Reviews, 2021, 20, 102702.	5.8	3
76	GPA-Induced Granulomatous Endocarditis Mimicking a Thrombotic Mitral Valve Stenosis. JACC: Case Reports, 2020, 2, 2151-2155.	0.6	2
77	FC 039RENAL OUTCOME AFTER RITUXIMAB IN ADULT-ONSET IGA VASCULITIS AND CRESCENTIC IGA NEPHROPATHY: A MULTICENTRE STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	2
78	Granulomatosis with Polyangiitis (Wegenerâ€™s Granulomatosis). , 2014, , 385-400.		2
79	Unclassified vasculitis. Clinical and Experimental Rheumatology, 2011, 29, S81-5.	0.8	2
80	Immunological changes and prevention of disease progression through elotuzumab therapy in refractory IgG4-related sclerosing mesenteritis. Rheumatology, 0, , .	1.9	2
81	Comment on: The nose is an organ too. Rheumatology, 2020, 59, e112-e113.	1.9	1
82	Increased frequency of IL-7 and IL-15 receptor alpha chain (CD127, CD215) co-expressing CD4(+) T cells in granulomatosis with polyangiitis (Wegener's). Clinical and Experimental Rheumatology, 2012, 30, S171.	0.8	1
83	Detection of anti-neutrophil cytoplasmic and antinuclear autoantibodies favouring misdiagnoses in 5 cases of Erdheim-Chester disease. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 176.	0.8	1
84	Circulating CD4+CD8+ double-positive T-cells display features of innate and adaptive immune function in granulomatosis with polyangiitis. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 93-98.	0.8	1
85	Wegener's Granulomatosis: A Pulmonary Perspective. Handbook of Systemic Autoimmune Diseases, 2004, 2, 63-94.	0.1	0
86	Small Vessel Vasculitides. , 2005, , 349-365.		0
87	THU0316â€...PROTEINASE-3 REGULATING MICRO-RNA IN GRANULOMATOSIS WITH POLYANGIITIS. , 2019, , .		0
88	SP0183â€...DIAGNOSIS AND TREATMENT OF HCV RELATED VASCULITIS. , 2019, , .		0
89	SAT0021â€...ELEVATED NUMBERS OF C-TYPE LECTIN CD161 POSITIVE PR3-SPECIFIC T-CELLS IN GPA. , 2019, , .		0
90	AB0207â€...RECEPTOR EXPRESSION OF ANGIOTENSIN TYPE-1 AND 2 ARE DECREASED IN PATIENTS WITH SYSTEMIC SCLEROSIS AND PULMONARY ARTERIAL HYPERTENSION(PAH) AND CORRELATED WITH SEROLOGICAL LEVELS OF NT-PROBNP. , 2019, , .		0

#	Article	IF	Citations
91	A patient with acute-onset hemorrhagic necroses and bullae of the legs. Rheumatology, 2021, 60, 5476-5477.	1.9	0
92	Small Vessel Vasculitides. , 2001, , 319-335.		0
93	Small Vessel Vasculitides. , 2011, , 389-403.		0
94	Expansion of CD161 expressing CD8+ single-positive and CD4+CD8+ double-positive PR3-specific T-cells in granulomatosis with polyangiitis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 182-183.	0.8	0
95	Expansion of CD161 expressing CD8+ single-positive and CD4+CD8+ double-positive PR3-specific T-cells in granulomatosis with polyangiitis. Clinical and Experimental Rheumatology, 2021, 39, 182-183.	0.8	0